|
1
|
Perry A, Louis DN, Scheithauer BW, Budka H
and Von Deimling A: Meningioma. WHO Classifications of Tumours of
the Central Nervous System. 4th edition. Louis DN, Ohgaki H,
Wiestler OD and Cavenee WK: International Agency for Research on
Cancer; Lyon: pp. 164–172. 2007
|
|
2
|
Love S, Louis DN and Ellison DW:
Greenfield’s Neuropathology. 8th edition. Hodder Arnold; London:
2008
|
|
3
|
Louis DN, Ohgaki H, Wiestler OD and
Cavenee WK: World Health Organisation Classification of tumours of
the central nervous system. IARC Press; Lyon: 2007
|
|
4
|
Perry A, Scheithauer BW, Stafford SL,
Lohse CM and Wollan PC: ‘Malignancy’ in meningiomas: A
clinicopathologic study of 116 patients, with grading implications.
Cancer. 85:2046–2056. 1999.PubMed/NCBI
|
|
5
|
Bourboulia D and Stetler-Stevenson WG:
Matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs): Positive and negative regulators in
tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roy R, Zhang B and Moses MA: Making the
cut: Protease-mediated regulation of angiogenesis. Exp Cell Res.
312:608–622. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patel R and Leung HY: Targeting the
EGFR-family for therapy: Biological challenges and clinical
perspective. Curr Pharm Des. 18:2672–2679. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van Meter TE, Rooprai HK, Kibble MM,
Fillmore HL, Broaddus WC and Pilkington GJ: The role of matrix
metalloproteinase genes in glioma invasion: Co-dependent and
interactive proteolysis. J Neurooncol. 53:213–235. 2001. View Article : Google Scholar
|
|
9
|
Nuttall RK, Pennington CJ, Taplin J, Wheal
A, Yong VW, Forsyth PA and Edwards DR: Elevated membrane-type
matrix metalloproteinases in gliomas revealed by profiling
proteases and inhibitors in human cancer cells. Mol Cancer Res.
1:333–345. 2003.PubMed/NCBI
|
|
10
|
Stojic J, Hagemann C, Haas S, Herbold C,
Kühnel S, Gerngras S, Roggendorf W, Roosen K and Vince GH:
Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is
correlated with the WHO-grading of human malignant gliomas.
Neurosci Res. 60:40–49. 2008. View Article : Google Scholar
|
|
11
|
Hagemann C, Anacker J, Haas S, Riesner D,
Schömig B, Ernestus R-I and Vince GH: Comparative expression
pattern of Matrix-Metalloproteinases in human glioblastoma
cell-lines and primary cultures. BMC Res Notes. 3:293–302. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Zhang K, Chen X, Zhao C and Sun Z:
Epilysin is overexpressed in glioblastoma and related to clinical
outcome of patients. Med Oncol. 32:3632015. View Article : Google Scholar
|
|
13
|
Kirches E, Grunewald J, von Bossanyi P,
Szibor R, Plate I, Krüger S, Warich-Kirches M and Dietzmann K:
Expression of matrix metalloproteinases in a series of 12
meningiomas. Clin Neuropathol. 20:26–30. 2001.PubMed/NCBI
|
|
14
|
Nordqvist AC, Smurawa H and Mathiesen T:
Expression of matrix metalloproteinases 2 and 9 in meningiomas
associated with different degrees of brain invasiveness and edema.
J Neurosurg. 95:839–844. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rooprai HK, Van Meter TE, Robinson SD,
King A, Rucklidge GJ and Pilkington GJ: Expression of MMP-2 and -9
in short-term cultures of meningioma: Influence of histological
subtype. Int J Mol Med. 12:977–981. 2003.PubMed/NCBI
|
|
16
|
Okada M, Miyake K, Matsumoto Y, Kawai N,
Kunishio K and Nagao S: Matrix metalloproteinase-2 and matrix
metalloproteinase-9 expressions correlate with the recurrence of
intracranial meningiomas. J Neurooncol. 66:29–37. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
von Randow AJU, Schindler S and Tews DS:
Expression of extracellular matrix-degrading proteins in classic,
atypical, and anaplastic meningiomas. Pathol Res Pract.
202:365–372. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Barresi V, Vitarelli E, Tuccari G and
Barresi G: MMP-9 expression in meningiomas: A prognostic marker for
recurrence risk? J Neurooncol. 102:189–196. 2011. View Article : Google Scholar
|
|
19
|
Barresi V, Alafaci C, Caffo M, Barresi G
and Tuccari G: Clinicopathological characteristics, hormone
receptor status and matrix metallo-proteinase-9 (MMP-9)
immunohistochemical expression in spinal meningiomas. Pathol Res
Pract. 208:350–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Edwards DR, Handsley MM and Pennington CJ:
The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wildeboer D, Naus S, Amy Sang QX, Bartsch
JW and Pagenstecher A: Metalloproteinase disintegrins ADAM8 and
ADAM19 are highly regulated in human primary brain tumors and their
expression levels and activities are associated with invasiveness.
J Neuropathol Exp Neurol. 65:516–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qu M, Qiu BO, Xiong W, Chen D and Wu A:
Expression of a-disintegrin and metalloproteinase 10 correlates
with grade of malignancy in human glioma. Oncol Lett. 9:2157–2162.
2015.PubMed/NCBI
|
|
23
|
Brew K and Nagase H: The tissue inhibitors
of metalloproteinases (TIMPs): An ancient family with structural
and functional diversity. Biochim Biophys Acta. 1803:55–71. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Toft-Hansen H, Nuttall RK, Edwards DR and
Owens T: Key metalloproteinases are expressed by specific cell
types in experimental autoimmune encephalomyelitis. J Immunol.
173:5209–5218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clark IM, Swingler TE, Sampieri CL and
Edwards DR: The regulation of matrix metalloproteinases and their
inhibitors. Int J Biochem Cell Biol. 40:1362–1378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Murphy G and Nagase H: Localizing matrix
metalloproteinase activities in the pericellular environment. FEBS
J. 278:2–15. 2011. View Article : Google Scholar
|
|
27
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rocks N, Paulissen G, El Hour M, Quesada
F, Crahay C, Gueders M, Foidart JM, Noel A and Cataldo D: Emerging
roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie.
90:369–379. 2008. View Article : Google Scholar
|
|
29
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar
|
|
30
|
Nagashima G, Fujimoto T, Suzuki R, Asai J,
Itokawa H and Noda M: Dural invasion of meningioma: A histological
and immunohistochemical study. Brain Tumor Pathol. 23:13–17. 2006.
View Article : Google Scholar
|
|
31
|
Sarkar S, Nuttall RK, Liu S, Edwards DR
and Yong VW: Tenascin-C stimulates glioma cell invasion through
matrix metalloproteinase-12. Cancer Res. 66:11771–11780. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Okuducu AF, Zils U, Michaelis SA, Mawrin C
and von Deimling A: Increased expression of avian erythroblastosis
virus E26 oncogene homolog 1 in World Health Organization grade 1
meningiomas is associated with an elevated risk of recurrence and
is correlated with the expression of its target genes matrix
metalloproteinase-2 and MMP-9. Cancer. 107:1365–1372. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lettau I, Hattermann K, Held-Feindt J,
Brauer R, Sedlacek R and Mentlein R: Matrix metalloproteinase-19 is
highly expressed in astroglial tumors and promotes invasion of
glioma cells. J Neuropathol Exp Neurol. 69:215–223. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hagemann C, Anacker J, Ernestus RI and
Vince GH: A complete compilation of matrix metalloproteinase
expression in human malignant gliomas. World J Clin Oncol. 3:67–79.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nagase H and Murphy G: Tailoring TIMPs for
selective metalloproteinase inhibition. The Cancer Degradome.
Edwards D, Hoyer-Hansen G, Blasi F and Sloane BF: Springer Science;
New York: pp. 787–810. 2008, View Article : Google Scholar
|
|
36
|
Silveira Corrêa TC, Massaro RR, Brohem CA,
Taboga SR, Lamers ML, Santos MF and Maria-Engler SS: RECK-mediated
inhibition of glioma migration and invasion. J Cell Biochem.
110:52–61. 2010.PubMed/NCBI
|
|
37
|
Kodama T, Ikeda E, Okada A, Ohtsuka T,
Shimoda M, Shiomi T, Yoshida K, Nakada M, Ohuchi E and Okada Y:
ADAM12 is selectively overexpressed in human glioblastomas and is
associated with glioblastoma cell proliferation and shedding of
heparin-binding epidermal growth factor. Am J Pathol.
165:1743–1753. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Saftig P and Reiss K: The ‘A Disintegrin
And Metalloproteases’ ADAM10 and ADAM17: Novel drug targets with
therapeutic potential? Eur J Cell Biol. 90:527–535. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wernicke AG, Dicker AP, Whiton M, Ivanidze
J, Hyslop T, Hammond EH, Perry A, Andrews DW and Kenyon L:
Assessment of Epidermal Growth Factor Receptor (EGFR) expression in
human meningioma. Radiat Oncol. 5:46–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pistolesi S, Boldrini L, Gisfredi S, De
Ieso K, Camacci T, Caniglia M, Lupi G, Leocata P, Basolo F,
Pingitore R, et al: Angiogenesis in intracranial meningiomas:
Immunohistochemical and molecular study. Neuropathol Appl
Neurobiol. 30:118–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Barresi V and Tuccari G: Increased ratio
of vascular endothelial growth factor to semaphorin3A is a negative
prognostic factor in human meningiomas. Neuropathology. 30:537–546.
2010.PubMed/NCBI
|
|
42
|
Tsai WC, Chen Y, Huang LC, Lee HS, Ma HI,
Huang SM, Sytwu HK and Hueng DY: EMMPRIN expression positively
correlates with WHO grades of astrocytomas and meningiomas. J
Neurooncol. 114:281–290. 2013. View Article : Google Scholar : PubMed/NCBI
|
